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upregulated in mouse embryo fibroblasts (MEFs) de-E2F3—A Novel Repressor
rived from E2F3-deficient mice. They further demon-of the ARF/p53 Pathway strate that E2F3, most probably E2F3b, represses ex-
pression of Arf in normal MEFs while E2F1 and E2F3a
play a role in Arf activation in response to oncogenic
stress (Aslanian et al., 2004).
Repression of many E2F-responsive promoters in qui-The Arf tumor suppressor is a key component of the
escent cells is associated with binding of E2F4 and p130,p53 tumor surveillance pathway, and its expression is
and as the cells reenter the cell cycle, the E2F4/p130activated by abnormal proliferation signals. In a recent
complexes are replaced by E2F1, E2F2, and E2F3 (Taka-paper, Lees and coworkers investigate the regulation
hashi et al., 2000). Aslanian et al. demonstrate that occu-of Arf expression by E2Fs and demonstrate that in
pancy of the Arf promoter by E2F family members isnormal cells E2F3 is a pivotal repressor of Arf.
significantly different: it is occupied only by E2F3 in both
quiescent and proliferating cells. Furthermore, loss of
The p16INK4a/pRB/E2F and ARF/Mdm2/p53 tumor sup- E2F3 results in elevated expression of Arf (Aslanian et
pressor pathways are malfunctioning in most, if not all, al., 2004). These findings may explain why Arf is not
human tumors, emphasizing their critical role in the con- periodically expressed during the cell cycle: an intrigu-
trol of cancer development (Sherr and McCormick, ing option is that under conditions in which the activator
2002). Evidence accumulated over the past few years E2Fs, E2F1, 2, and 3a, can replace an E2F4/p130 com-
demonstrates that there is extensive crosstalk between plex (in late G1), they cannot replace E2F3b. A greater
the two pathways. One molecular link between them is affinity of E2F3b to its binding site may account for
the Arf tumor suppressor gene (p14ARF in humans and this phenomenon. Such a mechanism will ensure that
p19ARF in rodents) (Bates et al., 1998). The Arf gene different E2F-regulated genes are activated when the
serves as a sensor of hyperproliferative signals that are total amount of activator E2Fs crosses different thresh-
generated by deregulated oncogenes, and its expres- olds: most E2F-responsive genes will be activated by
sion is upregulated by E1a, v-abl, oncogenic Ras, and the E2F signal that is generated during normal prolifera-
overexpression of Myc or E2F1 (Sherr, 2001). Once it is tion, but unique E2F-responsive genes such as Arf, and
expressed, ARF interacts with the Mdm2 E3 ubiquitin perhaps additional genes, will not be activated at this
ligase, and inhibits its ability to target p53 for ubiquitina- point. They will be activated only by higher levels of
tion and subsequent degradation. Thus, an oncogenes- E2F activity, which are present during abnormal and
induced increase in ARF levels leads to p53 stabilization uncontrolled proliferation. Additional experiments are
and activation (Lowe and Sherr, 2003). In addition, ARF required to test this hypothesis. Furthermore, it remains
has p53-independent antiproliferative activities (Lowe to be determined how E2F3b “chooses” the Arf pro-
and Sherr, 2003). moter out of the many E2F-regulated promoters and
Despite the activation of Arf expression by deregu- whether additional E2F-regulated genes are subjected
lated or overexpressed E2F, and unlike most E2F-regu- to E2F3-mediated repression and are, therefore, also
lated genes, Arf expression does not change signifi- activated only in response to abnormal signaling
cantly during the cell cycle (Lowe and Sherr, 2003). An thresholds.
important and unresolved question is, how does the A number of additional interesting questions remain
Arf promoter respond to E2F activity during abnormal unanswered and will probably be the focus of future
proliferation but not during normal proliferation? An- studies: Which of the E2F3s represses Arf expression?
other unresolved issue is the identity of the E2F family Is it a unique function of E2F3b? Who are the corepres-
member(s) that regulates Arf expression. The E2F family sors that function together with E2F3? Answering these
comprises at least eight related transcription factors questions awaits the generation of mice and cells defi-
designated E2F1-7. E2F1, 2, and 3a are activators of cient in individual E2F3s as well as a careful analysis of
gene expression and E2F3b, 4, 5, 6, and 7 are mainly the repressive complexes on the Arf promoter.
involved in repression (DeGregori, 2002). E2F3a and Arf expression is regulated somewhat differently in
E2F3b are encoded by one genomic locus via the use mice and in humans. Also, loss of E2F3 has different
of different promoters (Leone et al., 2000). effects on the development of tumors derived from dif-
ferent tissues. Therefore, it will be important to testA recent paper by Aslanian et al. shows that Arf is
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whether E2F3 is a repressor of Arf also in other cell these proapoptotic genes is growth regulated peaking
types and other species. Notwithstanding these open at or near the G1/S transition. This implies that mecha-
questions, the identification of E2F3 as a pivotal repres- nisms acting downstream to their transcriptional activa-
sor of Arf is an important addition to our understanding tion may play a critical role in inhibition of E2F-induced
of how E2Fs control cell proliferation and apoptosis in apoptosis during normal growth. Unraveling these mo-
normal and transformed cells. lecular mechanism(s) remains a challenging problem.
The data presented by Aslanian et al. also imply that,
similarly to the INK4a/Arf locus, the E2F3 locus affects
the activity of the pRB/E2F and ARF/p53 pathways. Doron Ginsberg
However, while the products of the INK4a/Arf locus Department of Molecular Cell Biology
upregulate the activities of pRB and p53, the products The Weizmann Institute of Science
of the E2F3 locus, E2F3a and E2F3b, antagonize pRB Rehovot 76100
and ARF/p53 activities, respectively. This raises the in- Israel
teresting possibility that under some settings amplifica-
tion of the E2F3 locus may contribute to tumor develop- Selected Reading
ment, similarly to inactivation of the INK4a/Arf locus that
is observed in many human cancers (Ruas and Peters, Aslanian, A., Iaquinta, P.J., Verona, R., and Lees, J.A. (2004). Genes
Dev. 18, 1413–1422.1998). Indeed, amplification of the E2F3 locus was docu-
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note, the E2F3-mediated repression of Arf most proba-
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Sherr, C.J., and McCormick, F. (2002). Cancer Cell 2, 103–112.in part, to direct transcriptional activation of proapo-
ptotic genes including p73, Apaf-1, caspases, and BH3- Takahashi, Y., Rayman, J.B., and Dynlacht, B.D. (2000). Genes Dev.
14, 804–816.only proteins (Ginsberg, 2002). Unlike Arf, expression of
eri1 cells have an additional phenotype that cannotGPI-Anchor Synthesis:
be explained by increased Ras signaling: they grow nor-Ras Takes Charge mally at 23C but not at 37C. It is the investigation of
this ts (temperature-sensitive) phenotype that forms the
intriguing second part of the story published in the May
28 issue of Cell (Sobering et al., 2004). Levin and col-
A new study shows that Ras2 regulates GPI-anchor leagues show that eri1 cells are extremely sensitive to
synthesis in the ER. Reciprocally, the targeted enzyme lysis at the nonpermissive temperature, a phenotype
GPI-GlcNAc transferase regulates Ras2 signal output. that is rescued by increasing the osmotic pressure of
This novel intersection of Ras2 signaling and an ER- the growth media and therefore indicative of a cell wall
localized protein complex has interesting implications defect. A genetic screen for multicopy suppressors of ts
for Ras function. growth then turned up GFA1, an enzyme that catalyzes
production of glucosamine-6-phosphate—the rate-lim-
Eri1 (for endoplasmic reticulum-associated Ras inhibitor iting step for UDP-N-acetylglucosamine (UDP-GlcNAc)
1) was recently isolated in a genetic screen for yeast production. The conclusion that GFA1 drives up cellular
with growth defects that were additive with defective levels of glucosamine-6-phosphate to compensate for
protein kinase C: a regulator of cell wall biogenesis (So- loss of Eri1 was confirmed by showing a similar rescue
bering et al., 2003). Interestingly, eri1 yeast are heat of growth at 37C if eri1 cells were supplied with an
shock sensitive and grow invasively on agar, pheno- exogenous source of glucosamine.
types that indicate hyperactive Ras signaling. The heat UDP-GlcNAc is used for protein N-glycosylation, and
shock sensitivity of eri1 strains is milder than that in- the synthesis of chitin and GPI-anchors. Chitin and GPI-
duced by constitutively active Ras2Val19 but is sup- anchored proteins are, respectively, minor and major
pressed by deleting Ras2 or overexpressing Ira2 (a structural components of the yeast cell wall. Defects in
GTPase activating protein). Eri1 and Ras2 form a com- N-glycosylation and chitin synthesis were excluded by
plex when coexpressed in yeast, although immunofluo- showing normal maturation of N-glycosylated CPY and
rescence microscopy shows Eri1 is localized to the en- by the finding that chitin synthesis is actually increased,
partly because of an upregulation of endogenous GFA1doplasmic reticulum (ER).
